Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 19

Showing 19 citing articles:

A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance
Yi Lei, Xin Jiang, Zaigang Zhou, et al.
Advanced Materials (2024) Vol. 36, Iss. 15
Closed Access | Times Cited: 23
Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance
Xin Jiang, Yi Lei, Cheng Li, et al.
ACS Nano (2024) Vol. 18, Iss. 4, pp. 3331-3348
Closed Access | Times Cited: 16
Mitochondria‐Targeted Nanoadjuvants Induced Multi‐Functional Immune‐Microenvironment Remodeling to Sensitize Tumor Radio‐Immunotherapy
Zaigang Zhou, Cheng Li, Chao Li, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 13
Therapeutic Immunomodulation in Gastric Cancer
Akkanapally Venu, Xue‐Feng Bai, Sujit Basu
Cancers (2024) Vol. 16, Iss. 3, pp. 560-560
Open Access | Times Cited: 9
Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape
S. S. Kirthiga Devi, S. D. Singh, Ramesh Joga, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2024) Vol. 200, pp. 114323-114323
Closed Access | Times Cited: 9
Mitochondrial metabolism blockade nanoadjuvant reversed immune-resistance microenvironment to sensitize albumin-bound paclitaxel-based chemo-immunotherapy
Zaigang Zhou, Wenjuan Luo, Chunjuan Zheng, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 9, pp. 4087-4101
Open Access | Times Cited: 7
Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy
Md. Ataur Rahman, Mahesh Kumar Yadab, Meser M. Ali
Cells (2024) Vol. 13, Iss. 22, pp. 1924-1924
Open Access | Times Cited: 6
A mitochondria-interfering nanocomplex cooperates with photodynamic therapy to boost antitumor immunity
Zhijie Zhang, Qingfu Zhao, Qingqing Xu, et al.
Biomaterials (2025) Vol. 317, pp. 123094-123094
Closed Access
Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation
Emmanuel Faderin, Terungwa H. Iorkula, Omowunmi Rebecca Aworinde, et al.
Medical Oncology (2025) Vol. 42, Iss. 2
Closed Access
Multifunctional Magnetic Ionic Liquid‐Carbon Nanohorn Complexes for Targeted Cancer Theranostics
Yun Qi, Eijiro Miyako
Small Science (2025)
Open Access
Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts
Jacqueline Schönherr, Philipp Seifert, Falk Gühne, et al.
Cancers (2024) Vol. 16, Iss. 1, pp. 235-235
Open Access | Times Cited: 4
PD-L1 at the crossroad between RNA metabolism and immunosuppression
Axel Arthur, Sanae Nejmi, Don‐Marc Franchini, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 7, pp. 620-632
Closed Access | Times Cited: 3
Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles
Wen Zhang, Yi­hui Zhai, Ying Cai, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3218-3231
Open Access | Times Cited: 2
PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer
Kai Wang, Lili Yan, Xun Qiu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 6, pp. 167236-167236
Closed Access | Times Cited: 2
ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy
Dianlong Jia, Shiqi Zhao, Huimin Liu, et al.
International Journal of Biological Macromolecules (2024) Vol. 269, pp. 132058-132058
Closed Access | Times Cited: 1
Experimental Design and Characterization of Dual-Antibody-Conjugated All-Trans Retinoic Acid-loaded Lipid Nanoparticles as a Potential Cancer Therapy
Zeynep İşlek, Ali Asram Sağıroğlu, Mehmet Hikmet Üçışık, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 100, pp. 105995-105995
Closed Access | Times Cited: 1
Generation of a hetero-dye-labeled Quenchbody against programmed cell death-ligand 1
Sun‐Hee Kim, Haemin Park, Hee‐Jin Jeong
Biochemical Engineering Journal (2024) Vol. 204, pp. 109245-109245
Closed Access
Silver nanoparticle induced immunogenic cell death can improve immunotherapy
Ara Sargsian, Xanthippi Koutsoumpou, Hermon Girmatsion, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access
AIEgen-self-assembled nanoparticles with anti-PD-L1 antibody functionalization realize enhanced synergistic photodynamic therapy and immunotherapy against malignant melanoma
Li Lü, Qing Xu, Xiuzhen Zhang, et al.
Materials Today Bio (2024) Vol. 30, pp. 101387-101387
Open Access
Interaction of telmisartan and related sartans with the programmed cell death-ligand 1 (PD-L1) protein dimer: a molecular docking analysis
Gérard Vergoten, Christian Bailly
Future Journal of Pharmaceutical Sciences (2023) Vol. 9, Iss. 1
Open Access
Page 1

Scroll to top